Focused on the development of the UK cell therapy industry to increase the nation's health and wealth, it is to build its £55m state-of-the-art Cell Therapy manufacturing centre on the SBC campus.
The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise.
We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. The Cell Therapy Catapult is part-funded by Innovate UK, formerly the Technology Strategy Board – the UK’s innovation agency.
Looking forward to @Covance ATMP Symposium, with Dr Fungayi Chidothe, Strategy & Planning Lead, explaining how we are working to secure the #ATMP talent pipeline for future growth of the industry through the ATAC #apprenticeship programme. More info: ow.ly/O8WV50x7UwP pic.twitter.com/TUfjtoib9O